Your browser doesn't support javascript.
loading
Li-Fraumeni-associated pancreatic neuroendocrine tumour and XAF1 p.Glu134Ter risk modifier variant.
Riechelmann, Rachel P; Soares, Diogo C; Dias, Carla; Carraro, Dirce M; Torrezan, Giovana T.
Afiliação
  • Riechelmann RP; Department of Clinical Oncology, A.C. Camargo Cancer Center, Rua Antônio Prudente 211, São Paulo, SP 01509-010, Brazil.
  • Soares DC; Department of Oncogenetics, A.C. Camargo Cancer Center, Rua Antônio Prudente 211, São Paulo, SP 01509-010, Brazil.
  • Dias C; Department of Clinical Oncology, A.C. Camargo Cancer Center, Rua Antônio Prudente 211, São Paulo, SP 01509-010, Brazil.
  • Carraro DM; Instituto do Câncer do Estado de São Paulo, São Paulo, SP 01246-000, Brazil.
  • Torrezan GT; Genomics and Molecular Biology Group, International Research Center/CIPE, A.C. Camargo Cancer Center, Rua Antônio Prudente 211, São Paulo, SP 01509-010, Brazil.
Ecancermedicalscience ; 16: 1487, 2022.
Article em En | MEDLINE | ID: mdl-36819813
ABSTRACT
Studies have demonstrated that up to 17% of patients with pancreatic neuroendocrine tumours (pNETs) present pathogenic germline variants (PGVs) in several different genes, irrespective of family cancer history. Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome related to PGVs in the TP53 gene. A previous case of a pNET associated with LFS (c.1009C > T, p.R337C) has been reported. Here we report the first case of a patient with pNET and TP53 p.R337H and XAF1 p.E134* germline variants, expanding the knowledge of LFS and germline mutations in neuroendocrine tumours.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article